Fig. 2

Prognosis of AML patients with TET2 mutation. a pooled ORs and 95%CI for CR rate(OR 0.802; P = 0.176). b pooled HRs and 95%CI for EFS(HR 1.594; P = 0.002). c pooled HRs and 95%CI for OS in patients under 65 years of age(HR 1.310; P = 0.051)